New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
07:03 EDTANAC, NVSAnacor, Sandoz enter into agreement for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals (ANAC) announced that it has entered into an exclusive agreement with Sandoz, a Novartis (NVS) company, pursuant to which Sandoz will distribute and commercialize Anacorís drug KERYDIN topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, Anacor announced that the U.S. FDA approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. The agreement with Sandoz entitles Anacor to upfront payments totaling $40M and an additional milestone payment of $25M expected to be paid in January 2015. Under the agreement, Sandoz and Anacor will share equally, under a long-term profit-sharing arrangement, the gross profits accrued by Sandoz on sales of KERYDIN, except that in 2015 Anacor will start receiving profit-sharing payments after the first $50M of gross profits have been accrued by Sandoz. The long-term profit-sharing arrangement includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45M. Anacor will also have the option to repurchase all rights in KERYDIN from Sandoz on the later of three years from launch or December 31, 2017, at a price to be determined pursuant to the agreement. Under the terms of the agreement, Anacor will supply product to Sandoz at cost through Anacorís contract manufacturers, and Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialization of KERYDIN. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.
News For ANAC;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:40 EDTANACAnacor price target raised to $80 from $70 at Jefferies
Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
09:15 EDTANACAnacor price target raised to $85 from $72 at Wedbush
Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTANAC, NVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use